Type 2 Diabetes

In patients with type 2 diabetes currently taking metformin, treatment with combination exenatide plus insulin glargine decreased fasting glucose and resulted in greater weight loss compared to treatment with insulin lispro plus insulin glargine.

Study shows dulaglutide improved glycemic control in patients at 52 weeks compared to sitagliptin, but with a higher rate of adverse events.

Study shows a combination of liraglutide and the genetically modified insulin analog degludec was safe and improved HbA1c levels, weight loss, and hypoglycemia outcomes in patients with type 2 diabetes.

The Diabetes Resource Guide highlights 20 websites that feature articles on topics such as ways to address and improve lifestyle factors (such as diet), how to live day to day with diabetes, information about diabetes medications, online forums, and more.

Insulin sensitivity improved after three nights of adequate sleep in nondiabetic men after days of inadequate sleep.

Study results suggest that tight glycemic control is associated with decreased length of stay and improved mortality.

Results of a recent meta-analysis suggest lower rates of hypoglycemia with insulin degludec in obese patients when compared with insulin glargine.

Initial data show similar efficacy but different costs among injectable insulin treatments for patients who fail oral antidiabetic drugs.

A recent study suggests that skipping breakfast in overweight women may lead to insulin resistance.

Growing evidence suggests increased cardiovascular risk in patients with nonalcoholic fatty liver disease (NAFLD) - in particular nonalcoholic steatohepatitis (NASN) - but no data exists to support a specific management approach.

Inpatient management of patients with increasingly virulent community acquired and nosocomial infections, ranging from bacteremia to C. difficile colitis, presents hospitalists with challenging choices.

Results from a small study indicate patients with difficult-to-treat diabetic peripheral neuropathy (DPN) may benefit from therapy with tanezumab, a humanized monoclonal antibody against nerve growth factor.

In diagnosing a patient with type 2 diabetes, an endocrinologist or primary care physician may struggle with developing healthy treatment targets when comorbid conditions like obesity and hypoglycemia are at play.

Researchers say that new insight into the microbiome will lead to new opportunities for treating a variety of medical conditions, both within and outside the gut.

Over 10 years, lifestyle intervention and metformin were cost-effective or cost saving compared with placebo.

Researchers in Taiwan report that type 2 diabetes is independently associated with increased risk of peptic ulcer bleeding.

Severe neuropathic pain due to diabetic peripheral neuropathy is associated with negative health impact and increased healthcare utilization, underscoring the need for the development of safe and effective treatments.

Results from a new pilot study show early lifestyle intervention in obese pregnant women cuts their risk of developing gestational diabetes, as well as maternal and fetal complications that can emerge with high blood sugar.

Landmark study results presented at ACC.13 reveal patients with vascular disease treated with niacin therapy face increased risk of myopathy and other adverse events.

Many widely held beliefs about obesity and weight loss have no scientific basis.

The American Diabetes Association revised Standards of Medical Care for patients with diabetes include several changes in recommendations regarding testing and treatment goals.

Annual list highlights key studies and research that contribute to the prevention and treatment of cardiovascular diseases and stroke.

New research shows that arginase may contribute to angina in patients with type 2 diabetes. Suppressing the enzyme may help improve blood flow.

Results from the RELAX-AHF show serelaxin reduces cardiovascular deaths and improves symptoms in patients with heart failure.

Study results presented at AHA 2012 indicate that revascularization using CABG in diabetic patients with multivessel disease provides better clinical outcomes than PCI and is more cost effective in the long run.

Results from a sub-study of the Trial to Assess Chelation Therapy (TACT) that focused on quality of life issues in patients who had previously suffered a heart attack and were treated with chelation therapy reveal no improvements in these patients' quality of life.

Increasing numbers of people are on kidney transplant waiting lists. However, the number of potential living donors may shrink as more Americans qualify as pre-diabetic, making them less than ideal donor candidates.

Clinicians who treat patients with atypical antipsychotics should be aware of the weight gain potential associated with each medication in this class, and select the most appropriate medication to ensure patient compliance and prevent relapse.

New research suggests that Interpersonal Psychotherapy may be an effective option for treating major depression in patients with type 2 diabetes mellitus.